The challenge of antimicrobial resistance: new regulatory tools to support product development

Clin Pharmacol Ther. 2014 Aug;96(2):166-8. doi: 10.1038/clpt.2014.107. Epub 2014 May 13.


The antibiotic pipeline is thin and lacks diversity, particularly for agents targeting Gram-negative pathogens. The reasons for our anemic global development pipeline are often summarized as (i) discovery of new antibiotics is difficult, (ii) clinical development of new antibiotics is difficult, and (iii) the economics for new antibiotics are unfavorable for the developer. Here, we review recent efforts directed at the second of these challenges.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacokinetics
  • Clinical Trials as Topic / trends
  • Drug Discovery / legislation & jurisprudence*
  • Drug Discovery / trends*
  • Drug Resistance, Multiple, Bacterial / drug effects*
  • Drug Resistance, Multiple, Bacterial / physiology
  • Humans


  • Anti-Bacterial Agents